Reversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice
Authors:
- 18 August 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 20 (7) , 903-907
Abstract
Nicotine withdrawal symptoms are important factors in determining the relapse rate to tobacco smoking and drugs that diminish these symptoms would potentially have a higher success rate as smoking cessation aids. Unlike US Food and Drug administration approved smoke cessation aids (nicotine and varenicline) which act as nicotinic acetylcholine receptors (nAChRs) agonists, desformylflustrabromine (dFBr) acts as a nAChR positive allosteric modulator with higher selectivity to the α4β2 nAChR. In animal studies, dFBr was well tolerated and reduced intravenous nicotine self-administration. In this study, we use behavioral test in mouse model of spontaneous nicotine withdrawal to assess the effect of dFBr on nicotine withdrawal symptoms. Spontaneous nicotine withdrawal in nicotine-dependent ICR male mice was established 18–24 h after termination (minipump removal) of 14 days infusion of nicotine. After that (day 15), spontaneous signs of nicotine withdrawal were examined in the following order: anxiety-like behaviors, somatic signs, and then hyperalgesia using previously published behavioral protocols. Fifteen minutes before withdrawal signs testing, mice received a subcutaneous acute injection of vehicle or dFBr at the doses of 0.02, 0.1, and 1 mg/kg to determine the effect of dFBr on nicotine withdrawal symptoms. dFBr produced dose-dependent reversal of nicotine withdrawal signs in mouse model of spontaneous nicotine withdrawal. Positive allosteric modulators of nAChR such as dFBr reduce nicotine withdrawal symptoms supporting the potential clinical use of this novel class of nAChR-based therapeutics as smoking cessation aid.Keywords
Funding Information
- National Institute on Drug Abuse (DA-05274, DA-032246)
This publication has 20 references indexed in Scilit:
- Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in miceEuropean Journal of Pharmacology, 2016
- Photolabeling a Nicotinic Acetylcholine Receptor (nAChR) with an (α4)3(β2)2 nAChR-Selective Positive Allosteric ModulatorMolecular Pharmacology, 2016
- Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking CessationFrontiers in Molecular Neuroscience, 2015
- The therapeutic promise of positive allosteric modulation of nicotinic receptorsEuropean Journal of Pharmacology, 2014
- Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administrationPsychopharmacology, 2013
- Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: Advantages and limitationsBiochemical Pharmacology, 2011
- Nicotine addiction and nicotinic receptors: lessons from genetically modified miceNature Reviews Neuroscience, 2010
- Synthesis of desformylflustrabromine and its evaluation as an α4β2 and α7 nACh receptor modulatorBioorganic & Medicinal Chemistry Letters, 2007
- Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment.Molecular Pharmacology, 1992